EXCLUSIVE: Bexson Biomedical Inks Agreement With Stevanato For Delivery System Of Ketamine In Pain Management

Bexson Biomedical, a private company in the psychedelics space, has inked a new agreement with Stevanato Group, an Italian-based provider of drug delivery solutions.

Bexson is currently developing an improved version of ketamine called BB106, which allows for subcutaneous delivery of the drug. The company received a patent from the USPTO for this formulation in 2021.

Through this new agreement, Bexson will receive access to use one of Stevanato’s wearable delivery systems in a customized version developed by the two companies for using ketamine in …

Full story available on Benzinga.com

More EXCLUSIVE: Bexson Biomedical Inks Agreement With Stevanato For Delivery System Of Ketamine In Pain Management